Outcomes after approved immunotherapy for young blood cancer patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 0 to 26 years old (children and young adults)
- Have B-cell precursor acute lymphoblastic leukemia (ALL) or B-cell lymphoma
- Either have relapsed or refractory disease (came back or did not respond) or be getting standard immunotherapy as planned
- For Arm B: be in the process of getting treatment such as CAR T (tisagenlecleucel) or blinatumomab/inotuzumab, including planning for leukapheresis for CAR T
- Be able to provide consent (or, if under 18 or unable to consent, a parent/guardian/legal representative can consent)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental immunotherapy (PA3-17) designed to target and kill cancer cells that carry the CD7 marker in children and teens with T-cell leukemia or lymphoma that has returned or is hard to treat. It aims to see if the treatment is safe and effective at the best dose.
This trial tests a new CAR T-cell therapy made locally for children and young adults with B-cell cancers that have come back or not responded to other treatments. The therapy uses your own immune cells, modified to find and attack cancer cells.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
This study collects immune and tumor-related samples to learn what predicts response to adoptive cell therapy (a treatment using immune cells). If you (or your child) are eligible, you may help researchers understand who benefits and why.
Hear when a new Lymphoid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.